Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72 ... superiority phase 3 STEP UP trial (ClinicalTrials.gov ...

The company states: “Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the ... significant and superior weight loss at week 72 with semaglutide 7.2 mg versus ...

a 17.5% weight loss with semaglutide ... body weight at 72 weeks than adults receiving semaglutide 2.4 mg, according to top-line results from the STEP UP phase 3b trial. The trial enrolled 1,407 ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in ... and superior weight loss at week 72 with semaglutide 7.2 mg versus ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Key secondary endpoints included number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The ongoing 72-week STEP UP T2D trial will investigate semaglutide 7.2 mg in 512 ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP ... The trial achieved its primary endpoint by demonstrating a statistically significant and superior ...